Ocular Therapeutix (OCUL) Tops Q2 EPS by 16c

Ocular Therapeutix (NASDAQ: OCUL) reported Q2 EPS of ($2.10), $0.16 better than the analyst estimate of ($2.26). Revenue for the quarter came in at $97 thousand versus the consensus estimate of $100 thousand.

For earnings history and earnings-related data on Ocular Therapeutix (OCUL) click here.

You May Also Be Interested In

• Etsy upgraded to buy at BofA on durable growth, buyback potential
• Walmart (WMT) PT Lowered to $130 at Guggenheim
• Firm Capital Apartment REIT posts Q2 loss, plans name change